Table 1 Baseline characteristics of participants in STDP and Placebo group
From: Efficacy and safety of Shexiang Tongxin pill for coronary slow flow in angina patients
Baseline Characteristics | STDP group | Placebo group | p |
|---|---|---|---|
Age (years) | 60.30 (10.42) | 61.37 (8.87) | 0.435 |
Male | 64 (64.00) | 71 (71.72) | 0.285 |
Race, n (%) | |||
White | 0 | 0 | |
Asian | 100 (100%) | 99 (100%) | |
Black or African American | 0 | 0 | |
Others, n (%) | 0 | 0 | |
BMI (kg/m2) | 24.94 (3.08) | 25.03 (3.27) | 0.845 |
Smoking | 34 (36.17) | 39 (42.39) | 1.000 |
Hypertension | 46 (51.11) | 44 (49.44) | 0.823 |
Diabetes | 8 (8.99) | 20 (22.47) | 0.014 |
Hyperlipidemia | 25 (25.25) | 23 (23.23) | 0.740 |
SBP (mmHg) | 124.00 (110.00, 135.00) | 129.00 (116.00, 138.00) | 0.396 |
DBP (mmHg) | 80.00 (74.00, 87.00) | 80.00 (71.00, 89.00) | 0.909 |
Heart rate (beat per minute) | 72.00 (65.00, 80.00) | 70.00 (66.00,76.00) | 0.305 |
Course of angina pectoris (months) | 11.00 (1.00, 36.00) | 12.00 (1.00, 36.50) | 0.519 |
TC (mmol/L) | 5.79 (3.95) | 5.72 (5.12) | 0.095 |
TG (mmol/L) | 1.75 (1.05) | 1.72 (1.13) | 0.542 |
LDL-C (mmol/L) | 2.48 (0.88) | 2.41 (0.84) | 0.448 |
HDL-C (mmol/L) | 1.19 (0.32) | 1.08 (0.25) | 0.025 |
